Wuhan YZY Biopharma Co Ltd

Company Profile

• Business description

  Wuhan YZY Biopharma Co Ltd is a biotechnology company specifically involved in developing bispecific antibody-based therapies to treat cancer or cancer-associated complications, cancer, and age-related ophthalmologic diseases to address medical demands in oncology and aging-related ophthalmologic disease areas. The company has designed and developed various clinical-stage candidate drug pipelines, such as M701 (EpCAM CD3 bispecific antibody), Y101D, Y150, Y2019 (RBD dimer subunit SARS-CoV-2 vaccine), M802, and Y400 (VEGFxANG2 bispecific antibody) for the treatment of different cancer and age-related complications. Geographically, the company derives all of its revenue from the People's Republic of China (PRC).

• Contact

  No. 666 Gaoxin Road
  Building C2-1, Guanggu Biocity
  East Lake High Tech Development Zone
  Hubei Province
  Wuhan
  CHN

  T: +86 2782668988

  http://www.yzybio.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Biotechnology

  Fiscal Year End

  31 December 2025

  Employees

  113